The miR Sentinel™ Prostate Cancer Test is a standalone, non-invasive liquid biopsy urine test that accurately detects, classifies and can monitor prostate cancer at the molecular level.
Learn More.png)
The miR Disease Management Platform™ can transform cancer management by delivering actionable and accurate results to physicians and patients from a single urine sample, answering the two most important questions:
Is cancer present? How severe is it?
Our technology identifies molecular evidence of malignancies from the entire prostate gland, even in early onset of the disease, so if the test shows no molecular evidence of cancer, patients and physicians can confidently conclude that no cancer is present at the time of diagnosis.
Depending on the risk tolerance of patients and physicians, they may decide on monitoring the disease for progression non-invasively under an active surveillance protocol or elect to undergo a definitive treatment.
A significant percentage of prostate cancer patients have an indolent, or clinically insignificant localized cancer that may not require a definitive treatment. For patients with low risk classifications, a physician may recommend a follow up under an active surveillance protocol, which for patients could simply entail providing more urine samples periodically to ensure the disease has not progressed.
Patients whose molecular signature indicates the presence of high grade disease typically would undergo interventional definitive treatment, the specifics of which will be determined by the specialist care provider. Our technology identifies molecular evidence of the malignancies from the entire prostate gland, even in early onset of the disease.
Accelerate the right diagnosis and treatment for individual cancer management with accurate diagnosis and classification.
Help patients avoid the invasive, inaccurate, and painful diagnostic procedures that are the current standard of care. miR delivers results with zero contact.
Broaden access to life-saving cancer detection with a completely standalone urine test that detects and classifies prostate cancer with no additional testing requirements.
The miR Disease Management Platform™ is peer-reviewed and validated for the detection and classification of prostate cancer.
Quick turnaround of reliable information enables true cost-effectiveness in prostate cancer detection and management.
Unlike biopsies, MRIs and other current options, the miR platform is high-throughput and easily administered for large volumes of patients.
Prostate cancer is prevalent and deadly.
It represents the highest number of new cancer cases diagnosed annually and is the second leading cause of cancer deaths among men. Early detection and the ability to identify high grade disease early are key to effective disease management.
Invasive, expensive and inaccurate with 44% Sensitivity
Primary Care Visit
Urologist Visit
Multiple Digital Rectal Exams
Multiple PSA Blood Tests
1 or More Prostate Biopsies
Easily Administered, Pain-Free, Accurate, Non-Invasive, with >90% Sensitivity and Specificity
1 Urine Sample
Our non-invasive, pain-free prostate cancer detection platform helps healthcare providers, patients, and employers realize true cost-effectiveness and efficiency in prostate cancer detection and management for the first time.
Leverage the most accurate prostate cancer decision-making platform to help identify patients with the greatest need.
Experience a non-invasive, accurate, accessible prostate cancer test that delivers clear results to your doctor with a single urine specimen.
Keep your employees and their families healthy and reduce excessive urologic cancer screening, treatment costs and unproductive workdays with a straightforward, validated and highly accessible urine test.
Our molecular diagnostic capabilities are a novel approach to cancer detection and classification, using advanced sncRNA interrogation techniques and a proprietary scoring algorithm.
miR’s technology isolates pre-classified, informative RNA entities from urinary exosomes, and uses proprietary tools to detect and process signals from numerous RNA entities that are evident in the specimens.
The miR Sentinel™ Prostate Cancer Test is healthcare’s first and only standalone urine test that detects and classifies prostate cancers with a high level of accuracy—no rectal exam, blood test, biopsy or strict urine requirements.
miR’s test provides the most comprehensive non-invasive prostate cancer test.
.png)